Staphylococcus haemolyticus is part of the human normal skin microflora and is also found in nonhuman primates. This organism has been documented as a cause of primary and nosocomial bacteremia in clinical health care settings. Though CONS is ruled out as a contaminant, the emergence of multidrug-resistant isolates to glycopeptides, methicillin, fluoroquinolones, macrolides, lincosamides, streptogramin B and linezolid results in treatment failure in primary bacteremia. Transmission of resistant clones among Staphylococcus species necessitates the correct identification of Staphylococcus species for prompt treatment and identification plays a vital role in the prevention of nosocomial spread among healthcare workers. In this retrospective study we identified Staphylococcus haemolyticus from blood cultures sent to microbiology department from neonatal intensive care unit during the period from January to December 2018 by antimicrobial susceptibility testing and tested for various resistance patterns by CLSI standards. This study signifies the importance of identification of Staphylococcus haemolyticus species among CONS in neonatal sepsis and it's various resistance pattern to increase the antibiotic stewardship in clinical healthcare settings. | Multi drug resistant Staphylococcus haemolyticus an emerging nosocomial pathogen in neonatal sepsis at tertiary care centre, Thanjavur, India
